Why Lifecore Biomedical, Inc.’s (LFCR) Stock Is Up 6.15%

By Cynthia McLaughlin
August 03, 2026
Featured Tickers:

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Lifecore Biomedical, Inc. before investing.

In this article, we go over a few key elements for understanding Lifecore Biomedical, Inc.’s stock price such as:

  • Lifecore Biomedical, Inc.’s current stock price and volume
  • Why Lifecore Biomedical, Inc.’s stock price changed recently
  • Upgrades and downgrades for LFCR from analysts
  • LFCR’s stock price momentum as measured by its relative strength

About Lifecore Biomedical, Inc. (LFCR)

Before we jump into Lifecore Biomedical, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Want to learn more about Lifecore Biomedical, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Lifecore Biomedical, Inc..

Learn More About A+ Investor

What Caused Lifecore Biomedical, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Lifecore Biomedical, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Lifecore Biomedical, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Lifecore Biomedical, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Lifecore Biomedical, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Lifecore Biomedical, Inc. (LFCR) by visiting AAII Stock Evaluator.

Relative Price Strength of Lifecore Biomedical, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Lifecore Biomedical, Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 20 and is considered to be Very Weak.

Want to learn more about how Lifecore Biomedical, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Lifecore Biomedical, Inc. Stock Price: Bottom Line

As of July 31, 2026, Lifecore Biomedical, Inc.’s stock price is $4.420, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Lifecore Biomedical, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
O'Shaughnessy Tiny Titans
Screen:
23.7%
Annual Gain Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.